MYCB1

MYCB1 is a Dutch health-tech and pharmaceutical company that integrates high-quality medical cannabis products with a proprietary real-world evidence (RWE) platform. The company's core technology, Aletheia, utilizes machine learning and data analytics to collect and analyze patient-reported outcomes, enabling personalized cannabinoid therapies and evidence-based treatment protocols. MYCB1 produces a range of standardized, GMP-certified cannabis formulations, such as MYCB1-7, which are distributed through pharmacies to treat conditions like chronic pain and neurological disorders. By bridging the gap between traditional botanical medicine and modern pharmaceutical standards, the company aims to provide clinicians with the data necessary for confident prescribing. MYCB1 operates primarily in the European market, focusing on a 'pharmacy-first' distribution model and clinical validation.